



14th DIA Japan Annual Meeting 2017

November 12-14, 2017
Tokyo Big Sight | Ariake
DIAGlobal.org/Japan2017

PROGRAM CHAIR

Yasuhiro Fujiwara, MD, PhD
National Cancer Center

PROGRAM VICE-CHAIR

Akiko Ikeda, RPh
Janssen Pharmaceutical K.K.

PROGRAM COMMITTEE

Yoshikata Furuya, MSc
MSD K.K.

Natsuko Hamada
Eli Lilly Japan K.K.

Mitsuo Hayashi, MSc
MSD K.K.

Kanji Hirai, RPh
MSD K.K.

Akihiro Hirakawa, PhD
The University of Tokyo

Ayaka Hiramatsu, MPharm
Pharmaceuticals and Medical Devices Agency (PMDA)

Shinzo Hiroi, MPH, RPN, PMP
Takeda Pharmaceutical Co., Ltd.

Takahiro Inoue
Japan Agency for Medical Research and Development (AMED)

Kazuhiko Ishida, MS, RPh
Astellas Pharma Inc.,

Koji Iwasaki, PhD
Takeda Pharmaceutical Co., Ltd.

Masashi Kaichi
Japan Agency for Medical Research and Development (AMED)

Kazuhiro Kanmuri, PhD
Pfizer Japan Inc.

Chika Kiryu, DVM, PhD
Otsuka Pharmaceutical Co., Ltd.

Nobuhiro Koga, MBA, PMP
PAREXEL International Inc.,

Yoshiko Komuro, PhD
Pharmaceuticals and Medical Devices Agency (PMDA)

Kaori Muto, PhD
The University of Tokyo

Goshi Ozawa, MS, Lean Six Sigma Certified BB
Real Discovery Outdoors Co., Ltd.

Rie Matsui, RPh
Pfizer Japan Inc.

Takashi Sato, MSc, PMP
Kyowa Hakko Kirin Co., Ltd.

Yumi Sugiura, MRCP
Bristol-Myers Squibb K.K.

Atsushi Tsukamoto, PhD, MSc
Daiichi Sankyo Co., Ltd.

Keiko Tsumori
MSD K.K.

Hisashi Urushihara, DrPH, MS
Keio University

Koichiro Yuji, MD, PhD, FACP
The University of Tokyo

PROGRAM ADVISORS

Junichi Nishino, MSc, RPh
Novartis Pharma K.K.

Yoshihiko Ono, RPh
MSD K.K.

Junko Sato, PhD
Pharmaceuticals and Medical Devices Agency (PMDA)

OPERATION TEAM

Hiromi Okabe, PhD
Daiichi Sankyo Co., Ltd.

DIA volunteers, members, and staff provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications, and educational materials, throughout the year, all around the world.

DIAGlobal.org

CALL FOR ABSTRACTS

Please submit abstracts by **April 30, 2017**

Authors will be notified by **May 31, 2017**

Please submit all presentation abstracts using the online form at
DIAGlobal.org/Abstracts

For inquiries about abstract submission, please contact DIA Japan:
+81.3.6214.0574 | JapanAnnual@DIAGlobal.org

OVERVIEW

Professional individuals from all fields related to the mission of the DIA are invited to submit an abstract to be presented at the 14th DIA Japan Annual Meeting 2017 in Ariake, Tokyo held in November. The Professional Presentation Program* (oral presentation session and poster session**) is an opportunity for you to present your research to a diverse group of scientific professionals who are actively involved in the discovery, research and development, and life cycle management of pharmaceuticals, biotechnology, medical devices, and health care related products. The chair of the annual meeting and the program committee are inviting authors to submit abstracts for the presentation program which will deal with the below topics (see SUGGESTED ABSTRACT TOPICS).

* Your session time will be assigned by the chair and program committee members.

** Top quality abstracts that are submitted and accepted for poster presentation may be requested to change their presentation format to oral presentations.

SUGGESTED ABSTRACT TOPICS

- Artificial Intelligence
- Precision Medicine
- Development Strategy
- Regulatory Strategy
- Clinical trial operations (e.g. productivity, multi-regional clinical trials)
- New methodologies and tools for clinical trials (e.g. risk based monitoring, medical database, statistical approach, data management)
- Project management, cross-functional team management
- Pharmacovigilance and risk management
- Medical affairs/medical information
- Patient centricity
- Partnering/collaboration
- Quality
- Manufacturing

INSTRUCTIONS FOR SUBMISSION

- Abstract must be typed in English.
- Abstract must include the following contents:
 - Preferred format (**Oral** or **Poster** presentation. Please specify it in the Presentation Title field. Please also see the below "Note".)
 - Presentation title (Please see the below "Note".)
 - Author's full name, degrees, and institution (to be the primary/first author)
 - Background or Objectives (Maximum 300 Characters including spaces)
 - > Please provide a one sentence statement of the objective of the abstract.
 - Methods (Maximum 300 Characters including spaces)
 - > When, where, and how was the study was done? What materials were used or who was included in the study?
 - Results (Maximum 2000 Characters including spaces)
 - > What quantitative data was collected; what answer was found to the research question; what did the study find? Was the tested hypothesis true?
 - Conclusions (Maximum 2000 Characters including spaces)
 - > State what can be concluded from the study and its implications.
- Abstracts that describe just general information and common knowledge will not be accepted. Thus, new information, originality/uniqueness, and/or innovation should be included.
- Abbreviations should be avoided.
- Submission of an abstract is understood to imply that the article is original and is not being considered for publication elsewhere.

Note: When you start submission process, you may notice that "Poster Abstract" is selected as default abstract type, but it is just because of system operational reason. Please specify your preferred format, "Oral" or "Poster" presentation, in the "Title" field. For example, if your presentation title is "Future of AI" and you prefer oral presentation, please input "Future of AI (Oral)" in the Title field.

Tabletop and Exhibit Opportunities Available

For more information, please contact DIA Japan.
(The contact details are given below.)

Simultaneous Translation Available



DIA Japan

Nihonbashi Life Science Building 6F,
2-3-11 Nihonbashi-honcho, Chuo-ku, Tokyo 103-0023 Japan
Tel: +81.3.6214.0574 Fax: +81.3.3278.1313 Email: Japan@DIAGlobal.org

Drug Information Association

Global Center: Washington, DC | Americas | Europe, Middle East & Africa | China | Japan | India